In the wake of the great financial crisis it can sometimes be difficult for Intelligent Investors to find a solid financial company in which to invest, because they require specific achievements over the historical period. Â Many investors may simply decide to throw out the worst years with the rationale that they are outliers that shouldn’t be considered when evaluating the company’s prospects, but doing so would involve speculation.
We don’t know whether the financial crisis will happen again, but we do know that if it does, we can expect to see similar results as we did before.  By continuing to require the same standards for the historical period, Intelligent Investors are able to whittle down banks to only those with the best financial position, and then they are able to determine an intrinsic value to get a sense of whether the company is a good investment.
In addition, a company must have strong financial statements to prove that it is stable enough for Intelligent Investors.  This is best done by utilizing a systematic approach to analysis that will provide investors with a sense of how a specific company compares to another company.  By using the ModernGraham method one can review a company’s historical accomplishments and determine an intrinsic value that can be compared across industries.
What follows is a specific look at how Humana Inc. (HUM) fares in the ModernGraham valuation model.
Company Profile (obtained from Google Finance): Humana Inc. (Humana) is a health and well-being company. The Company operates in three segments: Retail, Employer Group and Healthcare Services. The Company’s medical and specialty insurance products allow members to access health care services through its network of health care providers. Its Retail Segment consists of products sold on a retail basis to individuals, including medical and supplemental benefit plans. Its Employer Group segment consists of products sold to employer groups, including medical and supplemental benefit plans, as well as health and wellness products. Its Healthcare Services segment consists of businesses, which offers services, including pharmacy solutions, provider services, home-based services, integrated behavioral health services, and predictive modeling and informatics services to other Humana businesses, as well as external health plan members, external health plans, and other employers or individuals.
[level-free]
To read the rest of this valuation, you must be logged in as a premium member. If you are not a premium member, please consider becoming one.
Premium members can view a full ModernGraham valuation of the company and have access to download a PDF version of the valuation for easy reference. Here is a free sample valuation pdf, and here is a post detailing what can be found within each individual company’s valuation.
[/level-free]
[level-mg-stocks-screens-subscriber]
Downloadable PDF version of this valuation:
ModernGraham Valuation of HUM – October 2015
Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?
What kind of Intelligent Investor are you?
Defensive Investor; must pass all 6 of the following tests. | ||||
1. Adequate Size of the Enterprise | Market Cap > $2Bil | $26,820,824,892 | Pass | |
2. Earnings Stability | Positive EPS for 10 years prior | Pass | ||
3. Dividend Record | Dividend Payments for 10 years prior | Fail | ||
4. Earnings Growth | Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end | 106.19% | Pass | |
5. Moderate PEmg Ratio | PEmg < 20 | 22.28 | Fail | |
6. Moderate Price to Assets | PB Ratio < 2.5 OR PB*PEmg < 50 | 2.68 | Fail | |
Score | ||||
Enterprising Investor; must pass all 3 of the following tests, or be suitable for the Defensive Investor. | ||||
1. Earnings Stability | Positive EPS for 5 years prior | Pass | ||
2. Dividend Record | Currently Pays Dividend | Pass | ||
3. Earnings Growth | EPSmg greater than 5 years ago | Pass |
Stage 2: Determination of Intrinsic Value
EPSmg | $8.04 |
MG Growth Estimate | 3.23% |
MG Value | $120.30 |
Opinion | Overvalued |
MG Value based on 3% Growth | $116.56 |
MG Value based on 0% Growth | $68.33 |
Market Implied Growth Rate | 6.89% |
Current Price | $179.11 |
% of Intrinsic Value | 148.88% |
Humana Inc. qualifies for the Enterprising Investor but not the more conservative Defensive Investor.  The Defensive Investor has concerns regarding the short dividend history and the high PEmg and PB ratios while the Enterprising Investor has no initial concerns. As a result, all Enterprising Investors following the ModernGraham approach based on Benjamin Graham’s methods should feel comfortable proceeding with the next stage of the analysis.
As for a valuation, the company appears to be overvalued after growing its EPSmg (normalized earnings) from $6.61 in 2011 to an estimated $8.04 for 2015.  This level of demonstrated earnings growth does not support the market’s implied estimate of 6.89% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on Benjamin Graham’s formula, returns an estimate of intrinsic value below the price.
The next part of the analysis is up to individual investors, and requires discussion of the company’s prospects.  What do you think?  What value would you put on Humana Inc. (HUM)?  Where do you see the company going in the future?  Is there a company you like better?  Leave a comment on our Facebook page or mention @ModernGraham on Twitter to discuss.
Stage 3: Information for Further Research
Graham Number | $116.81 |
PEmg | 22.28 |
PB Ratio | 2.68 |
Dividend Yield | 0.63% |
Number of Consecutive Years of Dividend Growth | 5 |
[/level-mg-stocks-screens-subscriber]
Useful Links:
ModernGraham tagged articles | Morningstar |
Google Finance | MSN Money |
Yahoo Finance | Seeking Alpha |
GuruFocus | SEC Filings |
Most Recent Balance Sheet Figures
Long-Term Debt | $3,823,000,000 |
Total Assets | $25,384,000,000 |
Intangible Assets | $3,266,000,000 |
Total Liabilities | $15,301,000,000 |
Shares Outstanding (Diluted Average) | 151,148,000 |
Earnings Per Share History
Next Fiscal Year Estimate | $8.91 |
Dec14 | $7.36 |
Dec13 | $7.73 |
Dec12 | $7.47 |
Dec11 | $8.46 |
Dec10 | $6.47 |
Dec09 | $6.15 |
Dec08 | $3.83 |
Dec07 | $4.91 |
Dec06 | $2.90 |
Dec05 | $1.87 |
Dec04 | $1.72 |
Dec03 | $1.38 |
Dec02 | $0.83 |
Dec01 | $0.70 |
Dec00 | $0.54 |
Dec99 | -$2.28 |
Dec98 | $0.77 |
Dec97 | $1.05 |
Dec96 | $0.07 |
Dec95 | $1.16 |
Earnings Per Share – ModernGraham History
Next Fiscal Year Estimate | $8.04 |
Dec14 | $7.57 |
Dec13 | $7.53 |
Dec12 | $7.12 |
Dec11 | $6.61 |
Dec10 | $5.41 |
Dec09 | $4.56 |
Dec08 | $3.53 |
Dec07 | $3.11 |
Dec06 | $2.05 |
Dec05 | $1.52 |
Dec04 | $1.24 |
Dec03 | $0.74 |
Dec02 | $0.32 |
Dec01 | $0.09 |
Dec00 | -$0.13 |
Dec99 | -$0.26 |
Recommended Reading:
Other ModernGraham posts about the company
Other ModernGraham posts about related companies
Disclaimer:
The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please review our detailed disclaimer.
Leave a Reply